Colistin Heteroresistance in Multidrug-Resistant Gram-Negative Bacilli

November 12, 2026 updated by: Aliaa Abdelhak Shehab, Assiut University

Phenotypic and Genotypic Detection of Colistin Heteroresistance Among Multidrug-Resistant Gram-Negative Bacilli in Assiut University Hospitals

This cross-sectional study aims to detect colistin heteroresistance phenotypically and genotypically among multidrug-resistant Gram-negative bacilli isolated from clinical specimens at Assiut University Hospitals.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Multidrug-resistant Gram-negative bacterial infections are a major clinical concern. Colistin is used as a last-line therapy, but heteroresistance (presence of resistant subpopulations within a susceptible isolate) may lead to treatment failure and is difficult to detect by routine methods.

This observational study will collect multidrug-resistant Gram-negative isolates that are intermediate to colistin by broth microdilution and will test them for heteroresistance using population analysis profile as the reference method, in addition to gradient strips (Etest) and disc diffusion. Molecular detection of related resistance genes will also be performed.

Study Type

Observational

Enrollment (Estimated)

75

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Multidrug-resistant Gram-negative bacterial isolates obtained from clinical specimens of hospitalized patients at Assiut University Hospitals.

Description

Inclusion Criteria:

  • - Multidrug-resistant Gram-negative isolates from clinical specimens
  • Colistin intermediate confirmed by broth microdilution

Exclusion Criteria:

  • Gram-positive bacteria
  • Carbapenem-sensitive Gram-negative bacteria
  • Repeated samples from the same patient
  • Colistin-resistant isolates confirmed by broth microdilution

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Multidrug-Resistant Gram-Negative Isolates

Clinical isolates of multidrug-resistant Gram-negative bacilli that are intermediate to colistin and will be tested for heteroresistance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of isolates with colistin heteroresistance
Time Frame: Baseline

Number of multidrug-resistant Gram-negative isolates showing colistin heteroresistance by population analysis profile test.

Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of isolates positive by Etest
Time Frame: Baseline

Number of isolates showing colistin heteroresistance by gradient strip (Etest) method.

Baseline
Number of isolates positive by disc diffusion
Time Frame: Baseline

Number of isolates showing colistin heteroresistance by disc diffusion method.

Baseline
Number of isolates carrying colistin heteroresistance-related genes
Time Frame: Baseline

Number of isolates positive for genes associated with colistin heteroresistance detected by conventional polymerase chain reaction.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Mohamed Z Abdel-rahman, prof, Clinical pathology Department, Assiut University Hospitals
  • Study Chair: Marwa M Mohammed, prof, Clinical pathology Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 26, 2026

Primary Completion (Estimated)

November 26, 2027

Study Completion (Estimated)

March 25, 2028

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Colistin-Heteroresistance-26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.